|
業務類別
|
Biotechnology |
|
業務概覽
|
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma. |
| 公司地址
| 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064 |
| 電話號碼
| +1 310 651-8041 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.immixbio.com |
| 員工數量
| 21 |
| Dr. Ilya Rachman |
Chairman of the Board and Chief Executive Officer |
美元 475.00K |
30/04/2025 |
| Mr. Gabriel Morris |
Chief Financial Officer, Principal Accounting Officer and Director |
美元 475.00K |
30/04/2025 |
| Dr. Graham Ross |
Acting Chief Medical Officer and Head of Clinical Development |
美元 88.59K |
30/04/2025 |
| Dr. Vladimir Torchilin |
Scientific Co-Founder |
-- |
30/04/2025 |
|
|
| Dr. Nancy T. Chang,PhD |
Director |
08/09/2025 |
| Ms. Jane M. Buchan, PhD |
Independent Director |
30/04/2025 |
| Ms. Helen C. Adams, C.P.A. |
Independent Director |
30/04/2025 |
| Dr. Magda Marquet, PhD |
Independent Director |
30/04/2025 |
| Ms. Yekaterina Chudnovsky |
Independent Director |
30/04/2025 |
| Mr. Jason Hsu |
Independent Director |
30/04/2025 |
| Dr. Ilya Rachman |
Chairman of the Board and Chief Executive Officer |
30/04/2025 |
| Mr. Gabriel Morris |
Chief Financial Officer, Principal Accounting Officer and Director |
30/04/2025 |
| Dr. Carey Ng |
Independent Director |
30/04/2025 |
|
|
|
|
